Astellas Pharma, Inc.’s Veozah (fezolinetant) for hot flashes caused by menopause got off to a slow commercial start, despite a high unmet need for nonhormonal treatment options for menopausal women. A new updated warning from the US Food and Drug Administration on a rare but serious risk of liver injury could further complicate the commercial ramp.
Veozah Warning On Liver Injury Could Present New Commercial Roadblock
The US FDA updated labeling for Astellas’ drug for hot flashes after a postmarketing report of a single patient with signs and symptoms of liver injury taking the medicine.
More from Women's Health
More from Scrip
• By
The Danish firm is spending nearly $580m to repurchase up to 2.2 million shares
• By
The Texas-based firm is giving up on the investigational Alzheimer’s therapy after a second Phase III failure left it with nowhere to go in the disease.
• By
Kyoto-based venture moves HQ to California to expand R&D and business outreach for its regulatory T-cell technology, as it raises around $46m in public and private funding.